person · Reporting owner
PATEL SAMIR CHANDRAKANT
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | April 10, 2025 | April 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date April 10, 2025 · Filed April 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 2035-04-09 | Direct | 18,000 |
Reported balance
After 2025-04-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IVERIC bio, Inc.
Report date December 31, 2016 · Filed February 14, 2017
Section 16 reporting ended · disclosed 2017-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,531 |
Reported balance
After 2016-08-10 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2016-08-10 · Gift · Disposed 30,000 · Balance 11,531 F1: Bona fide gift of securities to charity. |
| Common StockSEC Table I · non-derivative | Direct | 11,531 |
Reported balance
After 2016-08-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-08-11 · Gift · Disposed 90,000 · Balance 11,531 F2: Bona fide gift of securities to a trust, which is administered by an independent trustee, and is for the benefit of the reporting person's immediate and other family members. |
Filing footnotes · ownership attribution and instrument terms
F1: Bona fide gift of securities to charity.
F2: Bona fide gift of securities to a trust, which is administered by an independent trustee, and is for the benefit of the reporting person's immediate and other family members.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 10, 2025 Filed Apr 11, 2025 21:04 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053369 · ownership.xml · derivative · entry 1 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:44 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (right to buy) · Derivative | 105,913 | Not disclosed Strike: $0.85 | Not disclosed |
DisclosureSEC source: 0000950170-25-041496 · ownership.xml · derivative · entry 3 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,913 Underlying: Common Stock · 105,913 shares Expires 2034-05-27 F4 · date: Stock option assumed in connection with the closing of the Merger, in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement. F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of October 1, 2023, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:44 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantCommon Stock | 100,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-041496 · ownership.xml · nonDerivative · entry 2 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 100,800 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such, transaction, the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. F3 · ownership.nature: These securities are held directly by S&S New Hampshire Trust (the "S&S Shares") for the benefit of the reporting person's children. The reporting person may be deemed to have beneficial ownership over the S&S Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:44 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantCommon Stock | 252,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-041496 · ownership.xml · nonDerivative · entry 1 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such, transaction, the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 815 | $4.96 | $4,042.40 |
DisclosureSEC source: 0001104659-17-001232 · a4.xml · nonDerivative · entry 4 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,813 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2017. F3 · price: These shares were disposed of in multiple transactions on January 5, 2017 at actual sales prices ranging from $4.90 to $5.04 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 3,029 | $4.96 | $15,023.84 |
DisclosureSEC source: 0001104659-17-001232 · a4.xml · nonDerivative · entry 3 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,628 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2017. F3 · price: These shares were disposed of in multiple transactions on January 5, 2017 at actual sales prices ranging from $4.90 to $5.04 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-001232 · a4.xml · derivative · entry 6 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 Underlying: Common Stock · 1,325 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F5 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 5,300 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-001232 · a4.xml · derivative · entry 5 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 4,925 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 19,700 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 1,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001232 · a4.xml · nonDerivative · entry 2 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 4,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001232 · a4.xml · nonDerivative · entry 1 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 17:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 2,999 | $4.90 | $14,695.10 |
DisclosureSEC source: 0001104659-17-000648 · a4.xml · nonDerivative · entry 2 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,407 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 2, 2017. F3 · price: These shares were disposed of in multiple transactions on January 3, 2017 at actual sales prices ranging from $4.85 to $4.98 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000648 · a4.xml · derivative · entry 3 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 Underlying: Common Stock · 4,875 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units F4 · derivative.exercise_date: On January 2, 2015, the reporting person was granted an award of 19,500 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 4,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-000648 · a4.xml · nonDerivative · entry 1 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 2,000 | $56.90 | $113,800.00 |
DisclosureSEC source: 0001104659-16-148308 · a4.xml · nonDerivative · entry 4 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,531 F1 · kind: The sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2015. F5 · price: These shares were disposed of in multiple transactions on September 29, 2016 at actual sales prices ranging from $56.61 to $57.53 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 8,096 | $55.75 | $451,352.00 |
DisclosureSEC source: 0001104659-16-148308 · a4.xml · nonDerivative · entry 3 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,531 F1 · kind: The sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2015. F4 · price: These shares were disposed of in multiple transactions on September 29, 2016 at actual sales prices ranging from $55.47 to $56.23 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 2,612 | $54.93 | $143,477.16 |
DisclosureSEC source: 0001104659-16-148308 · a4.xml · nonDerivative · entry 2 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,627 F1 · kind: The sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2015. F3 · price: These shares were disposed of in multiple transactions on September 29, 2016 at actual sales prices ranging from $54.47 to $55.46 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 7,292 | $54.13 | $394,715.96 |
DisclosureSEC source: 0001104659-16-148308 · a4.xml · nonDerivative · entry 1 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,239 F1 · kind: The sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2015. F2 · price: These shares were disposed of in multiple transactions on September 29, 2016 at actual sales prices ranging from $53.47 to $54.46 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 11, 2016 Filed Feb 14, 2017 17:22 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GiftCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-009360 · a5.xml · nonDerivative · entry 2 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,531 F2 · kind: Bona fide gift of securities to a trust, which is administered by an independent trustee, and is for the benefit of the reporting person's immediate and other family members. Read SEC document |
| August 10, 2016 Filed Feb 14, 2017 17:22 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-009360 · a5.xml · nonDerivative · entry 1 PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,531 F1 · kind: Bona fide gift of securities to charity. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.